- Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018 | Phase 4 | Interventional
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
Phoenix Children's Hospital
Phoenix,Arizona,United States,85016
University of California, San Francisco Benioff Children's Hospital
San Francisco,California,United States,94143
University of Iowa
Iowa City,Iowa,United States,52242
Akron Children's Hospital
Akron,Ohio,United States,44647
Children's Hospital of Philadelphia
Philadelphia,Pennsylvania,United States,19104
Le Bonheur Children's Hospital
Memphis,Tennessee,United States,38105
Children's Specialty Group
Norfolk,Virginia,United States,23507
Alberta Children's Hospital
Calgary,Canada,T3B 6A8
University of Toronto The Hospital for Sick Children
Toronto,Canada,M5G 1X8
Study Eligibility Criteria
- Absence of CIDP symptoms
- History or family history of inherited neuropathy
- Diagnosed developmental delay or regression
- History of thrombotic episode
- Known or suspected hypersensitivity to Privigen
- Known allergic or other severe reactions to blood products
- Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study
- Pregnant or breastfeeding mother"
Additional Studies
Additional studies can be found at ClinicalTrials.gov